The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection

Yonsei University

Status

Unknown

Conditions

Colorectal Cancer

Treatments

Drug: Ketamine

Drug: Saline

Study type

Interventional

Funder types

Other

Identifiers

NCT03273231

4-2017-0475

Details and patient eligibility

About

Systemic inflammation caused by surgery may aggravate immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. ketamine, a N-methyl-D-asparate receptor antangonist, has anti-inflammatory activity and opioid-sparing effect. This study investigate the effect of intraopertaive ketamine administration on immune function in patients undergoing laparoscopic colorectal cancer resection.

Enrollment

100 estimated patients

Sex

All

Ages

20 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patient between 20 and 80 of age with ASA physical status Ⅰ-Ⅲ
patient scheduled for laparoscopic colorectal cancer resection

Exclusion criteria

ASA physical status Ⅳ
severe hepatorenal disease
heart failure
infection
increased intracranial pressure, seizure
preoperative chemotherapy
immune or endocrine disease
metastasis to other organ
problem with communication
pregnancy
body mass index > 35 kg/m2

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

100 participants in 2 patient groups, including a placebo group

ketamine group

Experimental group

Description:

Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.

Treatment:

Drug: Ketamine

control group

Placebo Comparator group

Description:

0.9% saline solution

Treatment:

Drug: Saline